Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results


1.		Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA015-0 NCT00073723

Last Modified: 2/8/2008 First Published: 1/23/2004


2.		Phase I/II Study of Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) (ABI-007) in Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-03111 ABI-CA015, NCT00077246


3.		Gemcitabine (GEMZAR) Plus ABI-007 (ABRAXANE)In Patients With Advanced Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA040 NCT00398086


4.		ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA013-0 NCT00046514

Last Modified: 5/4/2005 First Published: 3/24/2004


5.		Phase II Study of ABI-007 in Patients With Inoperable Locally Recurrent or Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0309060 ABI-CA014, NCT00081042

Last Modified: 7/24/2007 First Published: 5/28/2004


6.		Phase II Study of ABI-007, Carboplatin, and Trastuzumab (Herceptin®) in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 18				NCI, Pharmaceutical / Industry				MSKCC-04018 ABI-CA016, NCT00085605

Last Modified: 6/6/2007 First Published: 4/23/2005


7.		Phase II Study of ABI-007 and Gemcitabine in Women With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCCTG-N0531 N0531, NCT00110084


8.		Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				NSABP FB-AX-003 NCT00110695


9.		Neo-Adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				SCRI BRE 73 B9E-US-X437, NCT00193206


10.		A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-Line Treatment of Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75				Pharmaceutical / Industry				I-04-012 NCT00251472

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute